Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Spotlight on fraud as trustees are urged to make the Pledge
This month marks the fifth anniversary of our Pledge to Combat Pension Scams campaign. The threat of scammers is ever-present, and trustees and admi
Autumn Budget employer implications beyond the headlines
Recorded on the morning after the Chancellor's announcement, Barnett Waddingham's expert-led panel have unpacked the key outcomes and implic
Final Day for Voting in the 2025 Actuarial Post Awards
It's your last chance to vote in the 2025 Actuarial Post Awards as the voting window slams shut tonight. We have been celebrating and rewarding t

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.